On April 30, 2024 AGV Discovery reported that the first participant was dosed in the Phase 1/2 clinical trial for the evaluation of IPN01194 in patients with MAPKm advanced solid tumors (Press release, AGV Discovery, APR 30, 2024, View Source;refresh=665d5ac4a31081717394116 [SID1234643961]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cédric Boriès, President for AGV Discovery commented, "We are very pleased to announce the first dosing in humans of our drug candidate IPN01194 in collaboration with our partner Ipsen. This represents a very important milestone for us and for the patients we hope to serve. This success is the result and the demonstration of the efficiency of our drug design platform, based on innovative conception approaches".

The Phase 1/2 trial will evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and anti-tumors activity of ERK1/2 inhibitor IPN01194 as single agent in adult participants with advanced solid tumors.